表皮生长因子受体抑制剂在乳腺癌治疗中的研究

EGFR inhibitors in breast cancer

表皮生长因子受体(EGFR)抑制剂在非小细胞肺癌、头颈部肿瘤的治疗方面取得了较好的疗效。在乳腺癌方面,人们最初认为,EGFR的高表达也可能是乳腺癌病人接受EGFR抑制剂的重要条件,而EGFR抑制剂可能对ER阴性、内分泌治疗不敏感的乳腺癌有效。但临床研究结果并不支持上述观点。本文着重讨论EGFR抑制剂在乳腺癌治疗中的现状及前景。

EGFR inhibitor has got a promising efficacy in the treatment of non-small cell lung cancer and head and neck tumor.Therefore,it was expected that high levels of EGFR in breast tumors similarly might be a good criterion for selecting patients to receive EGFR inhibitors and EGFR inhibitors would prove most valuable in the treatment of ER -,endocrine-insensitive disease.However,emerging clinical experience in breast cancer is not supportive of this concept.This article seeks to address some issues that are important to the future success of EGFR-targeted therapies in breast cancer.